Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma

This study has been completed.

Study NCT00003204 Information provided by Eastern Cooperative Oncology Group

First Received: May 2, 2000 Last Updated: January 26, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	May 2006 (Final data collection date for primary outcome measure)

Publications:

Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T, Zhang L, Colocci N, Frankel S, Horning SJ. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol. 2009 Apr 1;27(10):1607-14. Epub 2009 Mar 2.

Colocci N, Weller E, Hochster HS, et al.: Prognostic significance of the Follicular Lymphoma International Prognostic Index (FLIPI) in the E1496 trial of chemotherapy with or without maintenance rituximab. [Abstract] J Clin Oncol 23 (Suppl 16): A-6526, 566s, 2005.

Hochster HS, Weller E, Gascoyne RD, et al.: Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. [Abstract] Blood 106 (11): A-349, 2005.

Hochster HS, Weller E, Ryan T, et al.: Results of E1496: a phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). [Abstract] J Clin Oncol 22 (Suppl 14): A-6502, 558s, 2004.

Hochster H, Weller E, Kuzel T, et al.: Increased mortality associated with higher dose cyclophosphamide plus fludarabine (CF) in advanced stage indolent lymphoma patients treated on E1496, an Eastern Cooperative Oncology Group (ECOG) and CALGB study. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1125, 2002.